BioCentury | Feb 28, 2020
Distillery Therapeutics

Sudan ebolavirus glycoprotein-targeting mAbs to treat Sudan virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Ebola A cocktail of two mAbs targeting the Sudan ebolavirus glycoprotein could treat infection by the virus. Identification of the antibody combination involved screening antibody libraries derived from mice and...
BC Innovations | Aug 23, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2019

New Therapeutic Targets and Biomarkers: July 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in July. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

mAb against GP38 glycoprotein for Crimean-Congo hemorrhagic fever virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Viral hemorrhagic fever A non-neutralizing mAb against GP38, an envelope glycoprotein from Crimean-Congo hemorrhagic fever virus, could prevent and treat infection. GP38 is a cleavage product of CCHFV GP. In...
BC Extra | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

Spero Therapeutics Inc. (NASDAQ:SPRO) said it will receive up to $54.2 million from the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) to develop SPR994. From BARDA, the company will...
BC Week In Review | May 25, 2018
Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
BC Extra | May 18, 2018
Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
BC Innovations | Mar 22, 2018
Emerging Company Profile

Hatching antibodies

OstriGen Inc. is developing polyclonal ostrich antibodies as oral therapies for cholera and other GI tract diseases that are designed to be as effective as existing mammalian antibodies while being produced at much lower costs....
BC Week In Review | Feb 9, 2018
Clinical News

Barvarian Nordic's smallpox vaccine meets in Phase III

Bavarian Nordic A/S (CSE:BAVA) reported data from an open-label Phase III trial showing that its Imvamune smallpox vaccine met the co-primary endpoints of non-inferiority to ACAM2000, an FDA-approved, second-generation smallpox vaccine from Emergent BioSolutions Inc....
BC Week In Review | Dec 6, 2016
Clinical News

Imvamune: Ph III started

Bavarian Nordic said the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) completed enrollment of 440 subjects in a Phase III trial comparing Imvamune vs. ACAM2000 , an FDA-approved, second-generation smallpox vaccine. The trial enrolled...
BC Week In Review | Mar 7, 2016
Company News

GeoVax Labs, USAMRIID deal

GeoVax and the institute partnered to develop a tetravalent vaccine against Ebola Zaire, Ebola Sudan, Marburg and Lassa fever viruses using GeoVax’s Modified Vaccinia Virus Ankara-Virus-Like Particle (MVA-VLP) vaccine platform. The partners will use anti-filovirus...
Items per page:
1 - 10 of 60
BioCentury | Feb 28, 2020
Distillery Therapeutics

Sudan ebolavirus glycoprotein-targeting mAbs to treat Sudan virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Ebola A cocktail of two mAbs targeting the Sudan ebolavirus glycoprotein could treat infection by the virus. Identification of the antibody combination involved screening antibody libraries derived from mice and...
BC Innovations | Aug 23, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: July 2019

New Therapeutic Targets and Biomarkers: July 2019 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database in July. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Jul 25, 2019
Distillery Therapeutics

mAb against GP38 glycoprotein for Crimean-Congo hemorrhagic fever virus infection

DISEASE CATEGORY: Infectious disease INDICATION: Viral hemorrhagic fever A non-neutralizing mAb against GP38, an envelope glycoprotein from Crimean-Congo hemorrhagic fever virus, could prevent and treat infection. GP38 is a cleavage product of CCHFV GP. In...
BC Extra | Jul 16, 2018
Company News

Spero nabs funding for antibiotic

Spero Therapeutics Inc. (NASDAQ:SPRO) said it will receive up to $54.2 million from the Biomedical Advanced Research and Development Authority (BARDA) and Defense Threat Reduction Agency (DTRA) to develop SPR994. From BARDA, the company will...
BC Week In Review | May 25, 2018
Company News

WHO to start treatment with Merck's Ebola vaccine

The World Health Organization began administering Ebola vaccine rVSV-ZEBOV (V920) from Merck & Co. Inc. (NYSE:MRK) on May 21 in two cities in the Democratic Republic of the Congo (DRC). Vaccination will be administered using...
BC Extra | May 18, 2018
Politics & Policy

WHO: Congo may approve mAb Zmapp for Ebola outbreak

The Democratic Republic of the Congo is likely to approve the use of Zmapp “in the coming days” to treat patients affected by the country's Ebola outbreak, the World Health Organization said Friday. President Larry...
BC Innovations | Mar 22, 2018
Emerging Company Profile

Hatching antibodies

OstriGen Inc. is developing polyclonal ostrich antibodies as oral therapies for cholera and other GI tract diseases that are designed to be as effective as existing mammalian antibodies while being produced at much lower costs....
BC Week In Review | Feb 9, 2018
Clinical News

Barvarian Nordic's smallpox vaccine meets in Phase III

Bavarian Nordic A/S (CSE:BAVA) reported data from an open-label Phase III trial showing that its Imvamune smallpox vaccine met the co-primary endpoints of non-inferiority to ACAM2000, an FDA-approved, second-generation smallpox vaccine from Emergent BioSolutions Inc....
BC Week In Review | Dec 6, 2016
Clinical News

Imvamune: Ph III started

Bavarian Nordic said the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) completed enrollment of 440 subjects in a Phase III trial comparing Imvamune vs. ACAM2000 , an FDA-approved, second-generation smallpox vaccine. The trial enrolled...
BC Week In Review | Mar 7, 2016
Company News

GeoVax Labs, USAMRIID deal

GeoVax and the institute partnered to develop a tetravalent vaccine against Ebola Zaire, Ebola Sudan, Marburg and Lassa fever viruses using GeoVax’s Modified Vaccinia Virus Ankara-Virus-Like Particle (MVA-VLP) vaccine platform. The partners will use anti-filovirus...
Items per page:
1 - 10 of 60